ME00230B - 2-(piridin -2-ilamino)-pirido(2,3-d) pirimidin-7-oni - Google Patents

2-(piridin -2-ilamino)-pirido(2,3-d) pirimidin-7-oni

Info

Publication number
ME00230B
ME00230B MEP-2008-461A MEP46108A ME00230B ME 00230 B ME00230 B ME 00230B ME P46108 A MEP46108 A ME P46108A ME 00230 B ME00230 B ME 00230B
Authority
ME
Montenegro
Prior art keywords
pyrimidin
pyrido
pyridin
cyclopentyl
ylamino
Prior art date
Application number
MEP-2008-461A
Other languages
English (en)
Inventor
Mark Robert Barvian
Richard John Booth
John Quin Iii
Joseph Thomas Repine
Derek James Sheehan
Scott Norman Vanderwel
Peter Laurence Toogood
Hairong Zhou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27613435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00230(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of ME00230B publication Critical patent/ME00230B/me
Publication of MEP46108A publication Critical patent/MEP46108A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)

Abstract

Ovaj pronalazak daje supstituisane 2-aminopiridine koji su korisni u liječenju proliferativnih oboljenja ćelija. Nova jedinjenja iz ovog pronalaska su potentni inhibitori ciklin-zavisnih kinaza 4 ( cdk4 ). (II). Ovaj pronalazak daje supstituisane 2-aminopiridine koji su korisni u liječenju proliferativnih oboljenja ćelija. Nova jedinjenja iz ovog pronalaska su potentni inhibitori ciklin-zavisnih kinaza 4 ( cdk4 ). (II).

Claims (15)

1. Jedinjenje formule I: I pri čemu: isprekidana linija predstavlja opcionu vezu, X1, X2 i X3 su u svakom slučaju nezavisno izabrani od vodonika, halogena, C1-C6 alkil, C1-C6 haloalkil, C1-C8 alkoksi, C1-C8 alkoksialkil, CN, NO2, OR5, NR5R6, CO2R5, COR5, S(O)nR5, conr5r6, nr5cor6, nr5so2r6, SO2NR5R6 i P(O)(OR5)(OR6) grupe; pod uslovom da najmanje jedan od X1, X2 i X3 mora da bude vodonik; n = 0-2 R1 je, u svakom slučaju, nezavisno, vodonik, halogen, C1-C6 alkil, C1-C6 haloalkil,C1-C6 hidroksialkil ili C3-C7 cikloalkil; R2 i R4 su nezavisno izabrani od vodonika, halogena, C1-C8 alkil, C3-C7 cikloalkil, C1-C8 alkoksi, C1-C8 alkoksialkil, C1-C8 haloalkil, C1-C8 hidroksialkil, C2-C8 alkenil, C2-C8 alkinil, nitril, nitro, OR5, SR5, NR5R6, N(O)NR5R6, P(O)(0R5)(OR6), (CR5R6)mNR7R8, COR5, (CR4R5)mC(0)R7, C02R5, CONR5R6, C(O)NR5SO2R6, NR5SO2R6, C(O)NR5OR6, S(O)nR5, SO2NR5R6, P(O)(OR5)(OR6), (CR5R6)mP(O)(OR7)(OR8), (CR5R6)m-aril, (CR5R6)m-heteroaril, -T(CH2)mQR5, -C(O)T(CH2)mR5, NR5C(O)T(CH2)mR5 i -CR5=CR6C(O)R7 grupe; ili R1 i R2 mogu da formiraju karbocikiičnu grupu koja sadrži prsten sa 3-7 članova, preferirano prsten sa 5-6 članova, od kojih do četiri člana može opciono da bude zamenjeno sa heteroatomom nezavisno izabranim od kiseonika, sumpora i azota, i pri čemu je karbociklična grupa nesupstituisana ili supstituisana sa jednom, dve ili tri grupe nezavisno izabrane od halogena, hidroksi, hidroksialkil, nitril, niže C1-C8 alkil, niže C1-C8 alkoksi, alkoksikarbonil, alkilkarbonil, alkilkarbonilamino, aminoalkil, trifluorometil, N-hidroksiacetamid, trifluorometilalkil, amino i mono ili dialkilamino, (CH2)mC(O)NR5R6 i O(CH2)mC(O)OR5 grupe, pod uslovom, međutim, da je u karbocikličnom prstenu najmanje jedan atom ugljenika i da, u koliko se nalaze dva ili više atoma kiseonika u prstenu, atomi kiseonika u prstenu se ne nalaze jedan pored drugog; T je O, S, NR7, N(O)R7, NR7R8W ili CR7R8 grupa; Q je O, S, NR7, N(O)R7, NR7R8W, CO2, O(CH2)m-heteroaril, O(CH2)mS(O)nR8, (CH2)-heteroaril ili karbociklična grupa koja sadrži 3-7 članova u prstenu, od kojih su do četiri člana prstena opciono heteroatomi nezavisno izabrani od kiseonika, sumpora i azota, pod uslovom, međutim, daje u karbocikličnom prstenu najmanje jedan atom ugljenika i da, u koliko se nalaze dva ili više atoma kiseonika u prstenu, atomi kiseonika u prstenu se ne nalaze jedan pored drugog, pri čemu je karbociklična grupa nesupstituisana ili supstituisana sa jednom, dve ili tri grupe nezavisno izabrane od halogena, hidroksi, hidroksialkil, niže alkil, niže alkoksi, alkoksikarbonil, alkilkarbonil, alkilkarbonilamino, aminoalkil, trifluorometil, N-hidroksiacetamid, trifluorometilalkil, amino i mono ili dialkilamino grupe; W je anjon izabran iz grupe koja sadrži hlorid, bromid, trifluoroacetat i trietilamonijum anjon; m = 0-6; R4 i jedan od X1, X2 i X3 mogu da formiraju aromatični prsten koji sadrži do tri heteroatoma nezavisno izabrana od kiseonika, sumpora i azota i koji je opciono supsituisan sa do 4 grupe nezavisno izabrane od halogena, hidroksi, hidroksialkil, niže alkil, niže alkoksi, alkoksikarbonil, alkilkarbonil, alkilkarbonilamino, aminoalkil, aminoalkilkarbonil, trifluorometil, trifluorometilalkil, trifluorometilaminoalkil, amino, mono- ili dialkilamino, N-hidroksiacetamido, aril, heteroaril, karboksialkil, nitril, NR7SO2R8, C(O)NR7R8, NR7C(O)R8, C(O)OR7, C(O)NR7SO2R8, (CH2)mS(O)nR7, (CH2)m-heteroaril, O(CH2)m-heteroaril, (CH2)mC(O)NR7R8, O(CH2)mC(O)OR7, (CH2)mSO2NR7R8 i C(O)R7 grupe; R3 je vodonik, aril, C1-C8 alkil, C1-C8 alkoksi, C3-C7 cikloalkil ili C3-C7 heterociklil grupa; R3 i R6 su nezavisno vodonik, C1-C8 alkil, C2-C8 alkenil, C2-C8 alkinil, arilalkil, cikloalkil, heterocikloalkil, aril, heteroaril ili heteroarilalkil grupa; ili R3 i R6, kada su vezani za isti atom azota, uzeti zajedno sa azotom za koji su vezani, grade heterociklični prsten koji sadrži od 3-8 članova u prstenu, od kojih do četiri člana može opciono da se zameni sa heteroatomima nezavisno izabranim od kiseonika, sumpora, S(O), S(O)2 i azota, pod uslovom, međutim, da je u karbocikličnom prstenu najmanje jedan atom ugljenika i da, u koliko se nalazi dva ili više atoma kiseonika u prstenu, atomi kiseonika u prstenu se ne nalaze jedan pored drugog, pri čemu je heterociklična grupa nesupstituisana ili supstituisana sa jednom, dve ili tri grupe nezavisno izabrane od halogena, hidroksi, hidroksialkil, niže alkil, niže alkoksi, alkoksikarbonil, alkilkarbonil, alkilkarbonilamino, aminoalkil, aminoalkilkarbonil, trifluorometil, trifluorometilalkil, trifluorometilalkilaminoalkil, amino, nitril, mono- ili dialkilamino, N-hidroksiacetamido, aril, heteroaril, karboksialkil, NR7SO2R8, C(O)NR7R8, NR7C(O)R8, C(O)0R7, C(O)NR7SO2R8, (CH2)mS(O)nR7, (CH2)m-heteroaril, O(CH2)m-heteroaril, (CH2)mC(O)NR7R8, O(CH2)mC(O)OR7 i (CH2)mSO2NR7R8 grupe; R7 i R8 su nezavisno vodonik, C1-C8 alkil, C2-C8 alkenil, C2-C8 alkinil, arilalkil, cikloalkil, heterocikloalkil, aril, heteroaril ili heteroarilalkil grupa; ili R7 i R8, kada su vezani za isti atom azota, uzeti zajedno sa azotom za koji su vezani, grade heterociklični prsten koji sadrži od 3-8 članova u prstenu, od kojih su četiri opciono heteroatomi nezavisno izabrani od kiseonika, sumpora, S(O), S(O)2 i azota, pod uslovom, međutim, da je u karbocikličnom prstenu najmanje jedan atom ugljenika i da, u koliko se u prestenu nalazi dva ili više atoma kiseonika, atomi kiseonika u prstenu se ne nalaze jedan pored drugog, pri čemu je heterociklična grupa nesupstituisana ili supstituisana sa jednom, dve ili tri grupe nezavisno izabrane od halogena, hidroksi, hidroksialkil, niže alkil, niže alkoksi, alkoksikarbonil, alkilkarbonil, alkilkarbonilamino, aminoalkil, aminoalkilkarbonil, trifluorometil, trifluorometilalkil, trifluorometilalkilaminoalkil, amino, nitril, mono- ili dialkilamino, N-hidroksiacetamido, aril, heteroaril, karboksialkil grupe i njihove farmaceutski prihvatljive soli, estri, amidi i prolekovi.
2. Jedinjenje u skladu sa patentnim zahtevom 1, naznačeno time što ima sledeću strukturu: pri čemu su R1, R2, R3, R4, X1, X2 i X3 kako je definisano za formulu I.
3.    Jedinjenje u skladu sa patentnim zahtevom 1 ili patentnim zahtevom 2, naznačeno time stoje R3 ciklopentil grupa.
4.    Jedinjenje u skladu sa patentnim zahtevom 2 ili patentnim zahtevom 3, naznačeno time što je R1 alkil grupa.
5.    Jedinjenje u skladu sa patentnim zahtevom 2 ili patentnim zahtevom 3, naznačeno time što je R1 metil grupa.
6.    Jedinjenje u skladu sa patentnim zahtevom 2 ili patentnim zahtevom 3, naznačeno time što je R2 (CO)CH3 grupa.
7. Jedinjenje u skladu sa patentnim zahtevom 1 naznačeno time što je izabrano iz grupe koja sadrži: 8-Ciklopenlil-2-(piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on hidrohlorid, 8-Ciklopentil-6-etil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on hidrohlorid, Etil estar hidrohlorid 8-ciklopentil-7-okso-2-(5-piperazin-l -il-piridin-2-ilamino)-7, 8-dihidro-pirido[2, 3-d]pirimidin-6-karboksilatne kiseline, 6-Amino-8-ciklopentil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on hidrohlorid, 6-Bromo-8-ciklopentil-2-[5-((R)-1-metil-l-pirolidin-2-il)-piridin-2-ilamino]-8H-pirido[2, 3-d]pirimidin-7-on hidrohlorid, 6-Bromo-8-cikloheksil-2-(piridin-2-il-amino)-8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-[5-(3, 5-dimetil-piperazin-l-il)-piridin-2-ilamino]-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-[5-(3, 3-dimetil-piperazin-l-il)-piridin-2-ilamino]-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-5-metil-2-[5-(4-metil-piperazin-l-il)-piridin-2-ilamino]-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-2-[5-(3-amino-pirolidin-l-il)-piridin-2-ilamino]-8-ciklopentil-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-5-metil-2-(5-morfolin-4-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 2-{5-[Bis-(2-metoksi-etil)-amino]-piridin-2-ilamino}-6-bromo-8-ciklopentil-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-5-metil-2-(5-morfolin-4-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-2-{5-[bis-(2-metoksi-etil)-amino]-piridin-2-ilamino}-8-ciklopentil-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, Terc-butil estar 4-[6-(8-ciklopentil-6-jodo-5-metil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino)-piridin-3-il]-piperazin-l-karboksilatne kiseline, 8-Ciklopentil-6-jodo-5-metil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, Terc-butil estar 4-[6-(8-ciklopentil-6-(2-etok. si-etoksi)-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino)-piridin-3-il]-piperazin-l-karboksilatne kiseline, 8-Ciklopentil-6-(2-etoksi-etoksi)-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 2-{5-[Bis-(2-metoksi-etil)-amino]-piridin-2-ilamino}-6-bromo-8-ciklopentil-5-metil-8H-pirido[2, 3-d]pirimidin 7 on, 6-Acetil-2-{5-[bis-(2-metoksi-etil)-amino]-piridin-2-ilamino}-8-ciklopentil-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, Terc-butil estar 4-[6-(8-izopropil-7-okso-7, 8-dihidro-pirido[2, 3]pirimidin-2-ilamino)-piridin-3-il]-piperazin-l-karboksilatne kiseline, 8-Izopropil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, Terc-butil estar 4-[6-(8-ciklopentil-7-okso-7, 8-dihidro-pirido[2, 3]pirimidin-2-ilamino)-piridin-3-il]-piperazin-1 -karboksilatne kiseline, 8-Ciklopentil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, Terc-butil estar 4-[6-(8-cikloheksil-7-okso-7, 8-dihidro-pirido[2, 3]pirimidin-2-ilamino)-piridin-3-il]-piperazin-l-karboksilatne kiseline, 8-Cikloheksil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, Terc-butil estar 4-[6-(8-ciklopropil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino)-piriđin-3-il ]-piperazin-1 -karboksilatne kiseline, 8-Ciklopropil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-(piridin-2, 6-ildiamino)-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-5-metil-2-(piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-5-metil-2-[5-(4-metil-piperazin-l-il)-piridin-2-ilamino]-8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-( 1 -etoksi-vinil)-5-metil-2-[5-(4-metil-piperazin-1 -il)-piridin-2-ilamino]-8H-pirido[2, 3-d]pirimidin-7-on, Terc-butil estar (l-{6-[8-ciklopentil-6-(l-etoksi-vinil)-5-metil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino]-piridin-3-il}-pirolidin-3-il)-karbamatne kiseline, 6-Acetil-8-ciklopentil-2-(4-hidroksi-3, 4, 5, 6-tetrahidro-2H-[l, 3']bipiridinil-6'-ilamino)-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, Terc-butil estar 4-[6-(6-bromo-8-ciklopentil-5-metil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-iilamino)-piridin-3-il]-azepan-1 -karboksilatne kiseline, 6-Bromo-8-ciklopentil-2-(5-[l, 4]diazepan-l-il-piridin-2-ilamino)-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, Terc-butil estar 4-{6-[8-ciklopentil-6-(l-etoksi-vinil)-5-metoksi-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino]-piridin-3-il}-[l, 4]diazepan-l-karboksilatne kiseline, 6-Acetil-8-ciklopentil-2-(5-[l, 4Jdiazepan-l-il-piridin-2-ilamino)-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-5-metil-2-(piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, Terc-butil estar 4-{6-[8-ciklopentil-5-metil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino)-piridin-3-il]-piperazin-l-karboksilatne kiseline, 8-Ciklopentil-5-metil-2-(5-piperazin-4-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, Terc-butil estar 4-[6-(6-bromo-8-ciklopentil-5-metil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino)-piridin-3-il]-2, 2-dimetil-piperazin-l-karboksilatne kiseline, 6-Bromo-8-ciklopentil-2-[5-(3, 3-dimetil-piperazin-l-il)-piridin-2-iilamino]-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, Terc-butil estar 4-{6-[8-ciklopentil-6-(l-etoksi-vinil)-5-metil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino]-piridin-3-il}-2, 2-dimetil-piperazin-l-karboksilatne kiseline, Terc-butil estar 4-[6-(6-bromo-8-ciklopentil-5-metil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino)-piridin-3-il]-2, 6-dimetil-piperazin-l-karboksilatne kiseline, 6-Bromo-8-ciklopentil-2-[5-(3, 5-dimetil-piperazin-l-il)-piridin-2-iilamino]-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, Terc-butil estar 4-{6-[8-ciklopentil-6-(l-etoksi-vinil)-5-metil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino]-piridin-3-il}-2, 6-dimetil-piperazin-l-karboksilatne kiseline, 8-Ciklopentil-6-(l-etoksi-vinil)-5-metil-2-(5-morfolin-4-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-5-metil-2-(3, 4, 5, 6-tetrahidro-2H-[l, 3']bipiridinil-6'-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-(l-etoksi-vinil)-5-metil-2-(3, 4, 5, 6-tetrahidro-2H-[1, 3']bipiridinil-6'-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-5-metil-2-(3, 4, 5, 6-tetrahidro-2H-[l, 3']bipiridinil-6'-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, Terc-butil estar 4-{6-[8-ciklopentil-6-(2-etoksi-etil)-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino]-piridin-3-il}-piperazin-l-karboksilatne kiseline, 8-Ciklopentil-6-(2-etoksi-etil)-2-(5-piperazin-l-il-piriđin-3-ilamino-8H-pirido[2, 3-d]pirimidin-7-on, Terc-butil estar 4-{6-[8-ciklopentil-6-(2-metoksi-etoksimetil)-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino]-piridin-3-il}-piperazin-l-karboksilatne kiseline, 8-Ciklopentil-6-(2-metoksi-etoksimetil)-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, Terc-butil estar 4-[6-(8-ciklopentil-6-etoksimetil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino)-piridin-3-il]-piperazin-1 -karboksilatne kiseline, 8-Ciklopentil-6-etoksimetil-2-(5-piperazin-1 -il-piridin-2-ilamino)- 8H-pirido[2, 3-d]pirimidin-7-on, Terc-butil estar 4-f6-(8-ciklopentil-6-metoksimelil-7-ukso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino)-piridin-3-il]-piperazin-l-karboksilatne kiseline, 8-Ciklopentil-6-metoksimetil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopenLil-2-[5-(2, 6-dirnetil-morfolin-4-il)-piridin-2-i1amino]-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-etoksimetil-2-(3, 4, 5, 6-tetrahidro-2H-[l, 3']bipiridinil-6'-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-etoksimetil-2-(5-morfolin-4-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, Benzil estar [8-ciklopentil-7-okso-2-(3, 4, 5, 6-tetrahidro-2H-[l, 3']bipiridinil-6'-ilamino)-7, 8-dihidro-pirido[2, 3-d]pirimidin-6-ilmetil]-karbamatne kiseline, 8-Ciklopentil-2-[5-(2, 6-dimetil-morfolin-4-il)-piridin-2-ilamino]-6-(l-etoksi-vinil)-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-[5-(2, 6-dimetil-morfolin-4-il)-piridin-2-ilamino]-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-5-metil-2-(5-piperazin-l-il-piridin-2-ilamino)-6-propionil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-metil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-5-metil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-fluoro-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on hidrohlorid, 8-Ciklopentil-6-metil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on hidrohlorid, 8-Ciklopentil-6-izobutoksi-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on hidrohlorid, 6-Benzil-8-ciklopentil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on hidrohlorid, 8-Ciklopentil-6-hidroksimetil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on hidrohlorid, Etil estar 2-[5-(4-terc-butoksikarbonil-piperazin-1 -il)-piridin-2-ilamino]-8-ciklopentil-5-metil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-6-karboksilatne kiseline, 6-Acetil-8-ciklopentil-2-(5-piperazin-l-il-piridin-2-ilamino-8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-5-metil-2-(5-piperazin-l-il-piridin-2-ilamino-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-5-metil-2-(piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-(piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-[5-(3, 5-dimetil-piperazin-l-il)-piridin-2-ilamino]-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-[5-(3, 3-dimctil-piperazin-l-il)-piridin-2-ilamino]-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-[5-(4-melil-piperaziii-l-il)-pindin-2-ilamino]-8H-pirido[2, 3-d]pirimidin-7-on, 2-[5-(3-Amino-pirolidin-l-il)-piridin-2-ilamino]-6-bromo-8-ciklopentil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-eiklopentil-2-[5-(3-etilamino-pirolidin-1-il)-piridin-2-ilamino]-8I I-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-(5-pirolidin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 2-{5-[3-(l-Amino-l-metil-etil)-pirolidin-l-il]-piridin-2-ilamino}-6-bromo-8-ciklopentil-8H-pirido[2, 3-d]pirimidin-7-on, l-[6-(6-Bromo-8-ciklopentil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino)-piridin-3-il]-pirolidin-2-karboksilatna kiselina, 6-Bromo-8-ciklopentil-2-[5-(4-dietilamino-butilamino)-piridin-2-ilamino]- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-[5-(3-etilamino-pirolidin-l-il)-piridin-2-ilamino]- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-5-metil-2-(5-pirolidin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-2-{5-[3-(l-amino-l-metil-etil)-pirolidin-l-il]-piridin-2-ilamino}-8-ciklopentil-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, 1-[6-(6-Acetil-8-ciklopentil-5-metil-7-okso7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino)-piridin-3-il]-pirolidin-2-karboksilatna kiselina, 6-Acetil-8-ciklopentil-2-[5-(4-dietilamino-butilamino)-piridin-2-ilamino]-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-2-[5-(3, 5-dimetil-piperazin-l-il)-piridin-2-ilamino]-6-etil-8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-2-[5-(3, 3-dimetil-piperazin-l-il)-piridin-2-ilamino]-6-etil-8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-etil-2-[5-(4-metil-piperazin-l-il)-piridin-2-ilamino]-6-etil-8H-pirido[2, 3-d]pirimidin-7-on, 2- [5-(3-Amino-pirolidin-l-il)-piridin-2-ilamino]-8-ciklopentil-6-etil-8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-etil-2-[5-(3-etilamino-pirolidinl-l-il)-piridin-2-ilamino]-6-etil-8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-etil-2-(5-pirolidin-1 -il-piridin-2-ilamino)-8II-pirido[2, 3-d]pirimidin-7-on, 2- {5-[3-( 1 -Amino-1 -metil-etil)-pirolidin-1 -il-piridin-2-ilamino}-8-ciklopentil-6-etil-8H-pirido[2, 3-d]pirimidin-7-on, l-[6-(8-Ciklopentil-6-etil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino)-piridin-3-il]-pirolidin-2-karboksilatna kiselina, 8-Ciklopentil-2-[5-(4-dietilamino-butilamino)-piridin-2-ilamino]-6-etil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Benzil-8-ciklopentil-2-[5-(3, 5-dimetil-piperazin-l-il)-piridin-2-ilamino]-8H- piriilo[2, 3-d]pirimidin-7-on, 6-Benzil-8-ciklopentil-2-[5-(3, 3-dimetil-piperazin-l-il)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 6-Benzil-8-ciklopentil-2-[5-(4-metil-piperazin-l-il)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 2-[5-(3-Amino-pirolidin-l-il)-piridin-2-ilamino]-6-benzil-8-ciklopentil-8H- pirido[2, 3-d]pirimidin-7-on, 6-Benzil-8-ciklopentil-2-[5-(3-etilamino-pirolidin-l-il)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 6-Benzil-8-ciklopentil-2-(5-pirolidin-l-il-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, 2- {5-[3-( 1 -Amino-1 -metil-etil)-pirolidin-1 -il]-piridin-2-ilamino} -6-benzil-8-ciklopentil-8H-pirido[2, 3-d]pirimidin-7-on, 1-[6-(6-Benzil-8-ciklopentil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino)-piridin-3-il]-pirolidin-2-karboksilatna kiselina, 6-Benzil-8-ciklopentil-2-[5-(4-dietilamino-butilamino)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-2-[5-(3, 5-dimetil-piperazin-l-il)-piridin-2-ilamino]-6- hidroksimetil-8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-2-[5-(3, 3-dimetil-piperazin-l-il)-piridin-2-ilamino]-6- hidroksimetil-8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-hidroksimetil-2-[5-(4-metil-piperazin-l-il)-piridin-2-ilamino]- 8H-pirido[2, 3-d]pirimidin-7-on, 2-[5-(3-Amino-pirolidin-l-il)-piridin-2-ilamino]-8-ciklopentil-6-hidroksimetil-8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-2-[5-(3-etilamino-pirolidin-l-il)-piridin-2-ilamino]-6- hidroksimetil-8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-hidroksimetil-2-(5-pirolidin-l-il-piridin-2-ilamino)-8H- pirido[2, 3-d]pirimidin-7-on, 2-{5-[3-(l-Amino-l-metil-etil)-pirolidin-l-il]-piridin-2-ilamino}-8-ciklopentil- 6-hidroksimetil-8H-pirido[2, 3-d]pirimidin-7-on, l-[6-(8-Ciklopentil-6-hidroksimetil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino)-piridin-3-il]-pirolidin-2-karboksilatna kiselina, 8-Ciklopentil-2-[5-(4-dietilamino-butilamino)-piridin-2-ilamino]-6- hidroksimetil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Amino-8-ciklopentil-2-[5-(3, 5-dimetil-piperazin-l-il)-piridin-2-ilamino]- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Amino-8-ciklopentil-2-[5-(3, 3-dimetil-piperazin-l-il)-piridin-2-ilamino]- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Amino-8-ciklopentil-2-[5-(4-metil-piperazin-l -il)-piridin-2-ilamino]-8H-pirido[2, 3-d]pirimidin-7-on, 6-Amino-2-[5-(3-aminu-pirulidiii-l-il)-pii'idin-2-ilamino]-8-ciklopenlil-8II- pirido[2, 3-d]pirimidin-7-on, 6-Aminn-8-ciklopentil-2-[5-(3-etilamino-pirolidin-l-il)-piridin-2-ilarnino]- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Aminu-8-eiklopenLil-2-(5-pirulidiii-l-il-pindin-2-ilamino)-8II-pirido[2, 3- d]pirimidin-7-on, 6-Amino-2-{5-[3-(l-amino-l-metil-etil)-pirolidin-l-il]-piridin-2-ilamino}-8- ciklopentil-8H-pirido[2, 3-d]pirimidin-7-on, 1-[6-(6-Amino-8-ciklopentil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino)-piridin-3-il]-pirolidin-2-karboksilatna kiselina, 6-Amino-8-ciklopentil-2-[5-(4-dietilamino-butilamino)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-(3, 4, 5, 6-tetrahidro-2H-[l, 3'[bipiridinil-6'-ilamino)-8H- pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-(5-morfolin-4-il-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-(5-dietilamino-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, 2-{5-[Bis-(2-hidroksi-etil)-amino]-piridin-2-ilamino}-6-bromo-8-ciklopentil-8H-pirido[2, 3-d]pirimidin-7-on, 2-{5-[Bis-(2-metoksi-etil)-amino]-piridin-2-ilamino}-6-bromo-8-ciklopentil- 8H-pirido[2, 3-d]pirimidin-7-on, 2-[5-(2-Amino-etilamino)-piridin-2-ilamino]-6-bromo-8-ciklopentil-8H- pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-(5-dimetilamino-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, N-[6-(6-Bromo-8-ciklopentil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2- ilamino)-piridin-3-il]-N-metil-acetamid, 6-Bromo-8-ciklopentil-2-[5-(2-metoksi-etoksi)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-[5-(2-metoksi-etoksimetil)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-[5-(2-dietilamino-etoksi)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-(5-pirolidin-l-il-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-(6-metil-5-piperazin-l-il-piridin-2-ilamino)-8H- pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-5-metil-2-(3, 4, 5, 6-tetrahidro-2II-[1, 3']bipiridinil-6'- ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-(5-dietilamino-piridin-2-ilamino)-5-metil-8H- pirido[2, 3-d]pirimidin-7-on, 2-{5-[Bis-(2-hidroksi-etil)-amino]-piridin-2-ilamino}-6-bromo-8-ciklopentil-5- metil-8H-pirido[2, 3-d]pirimidin-7-on, 2-[5-(2-Amino-etilamino)-piridin-2-ilamino]-6-bromo-8-ciklopentil-5-metil- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-(5-dimetilamino-piridin-2-ilamino)-5-metil-8H- pirido[2, 3-d]pirimidin-7-on, N-[6-(6-Bromo-8-ciklopentil-5-metil-7-okso-7, 8-dihidro-pirido[2, 3- d]pirimidin-2-ilamino)-piridin-3-il]-N-metil-acetamid, 6-Bromo-8-ciklopentil-2-[5-(2-metoksi-etoksi)-piridin-2-ilamino]-5-metil-8H- pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-[5-(2-metoksi-etoksimetil)-piridin-2-ilamino]-5- metil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-[5-(2-dietilamino-etoksi)-piridin-2-ilamino]-5-rnetil- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-5-metil-2-(5-pirolidin-l-il-piridin-2-ilamino)-8H- pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-5-metil-2-(6-metil-5-piperazin-l-il-piridin-2-ilamino)- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-5-metil-2-(3, 4, 5, 6-tetrahidro-2H-[l, 3']bipiridinil-6'- ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-(5-dietilamino-piridin-2-ilamino)-5-metil-8H- pirido[2, 3-d]pirimidin-7-on, 6-Acetil-2-{5-[bis-(2-hidroksi-etil)-amino]-piridin-2-ilamino}-8-ciklopentil-5- metil-8H-pirido[2, 3~d]pirimidin-7-on, 6-Acetil-2-[5-(2-amino-etilamino)-piridin-2-ilamino]-8-ciklopentil-5-metil-8H- pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-(5-dimetilamino-piridin-2-ilamino)-5-metil-8H- pirido[2, 3-d]pirimidin-7-on, N-[6-(6-Acetil-8-ciklopentil-5-metil-7-okso-7, 8-dihidro-pirido[2, 3- d]pirimidin-2-ilamino)-piridin-3-il]-en-metil-acetamid, 6-Acetil-8-ciklopentil-2-[5-(2-metoksi-etoksi)-piridin-2-ilamino]-5-metil-8H- pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-[5-(2-metoksi-etoksimetil)-piridin-2-ilamino]-5-metil- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-[5-(2-dietilamino-etoksimetil)-piridin-2-ilamino]-5- metil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-5-metil-2-(5-pirolidin-l-il-piridin-2-ilamino)-8H- pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-5-metil-2-(6-metil-5-piperazin-l-il-piridin-2-ilamino)- 8II-pirido[2,3-d]pirirnidin-7-on, 6-Acetil-8-ciklopentil-2-(3, 4, 5, 6'tetrahidro-2H-[ 1, 3']bipiridinil-6'-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-(5-morfolin-4-il-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-(5-dietilarnino-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, 6-Acetil-2'{5-[bis-(2-hidroksi-etil)-aminoj-piridin-2-ilamino}-8-ciklopenlil- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-2-{5-[bis-(2-metoksi-etil)-amino]-piridin-2-ilamino}-8-ciklopentil- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-2-[5-(2-amino-etilamino)-piridin-2-ilamino]-8-ciklopentil-8H- pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-(5-dimetilamino-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, N-[6-(6-Acetil-8-ciklopentil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2- ilamino)-piridin-3-il]-N-metil-acetamid, 6-Acetil-8-ciklopentil-2-[5-(2-metoksi-etoksi)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-[5-(2-metoksi-etoksimetil)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-[5-(2-dietilamino-etoksi)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-(5-pirolidin-l-piridin-2-ilamino)-8H-pirido[2, 3- dJpirimidin-7-on, 6-Acetil-8-ciklopentil-2-(6-metil-5-piperazin-l-piridin-2-ilamino)-8H- pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-[5-(2-metoksi-etoksi)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-[5-(2-metoksi-etilamino)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 2-(5-Azetidin-l-il-piridin-2-ilamino)-6-bromo-8-ciklopentil-8H-pirido[2, 3- d]pirimidin-7-on, 2-(5-Azepan-l-il-piridin-2-ilamino)-6-bromo-8-ciklopentil-8H-pirido[2, 3- d]pirimidin-7-on, N-[6-(6-Bromo-8-ciklopentil-2-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2- ilamino)-piridin-3-il]-acetamid, 6-Bromo-8-ciklopentil-2-(5-fenilamino-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-[5-(4-fluoro-benzilamino)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, N-[6-(6-Bromo-8-ciklopentil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2- ilamino)-piridin-3-il]-metansulfonamid, 6-Bromo-8-ciklopentil-2-(5-metansulfonil-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, 6-Bromo-8-ciklopentil 2-(5-fenil-piridin-2-ilamino)-8H-pirido[2! 3-d]pirimidin-7-on, 6-Amino-8-ciklopenLil-2-[5-(2-metoksi-etoksi)-piridin-2-ilamino]-8II- pirido[2! 3-d]pirimidin-7-on, 6-Amino-8-ciklopentil-2-[5-(2-metoksi-etilamino)-piridin-2-ilamino]-8li- pirido[2, 3-d]pirimidin-7-on, 6-Amino-2-(5-azetidin-l-il-piridin-2-ilamino)-8-ciklopentil-8H-pirido[2, 3- d]pirimidin-7-on, 6-Amino-2-(5-azepan-l-il-piridin-2-ilamino)-8-ciklopentil-8H-pirido[2, 3- d]pirimidin-7-on, N[6-(6-Amino-8-ciklopentil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2- iiamino)-piridin-3-il]-acetamid, 6-Amino-8-ciklopentil-2-(5-fenilamino-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, 6-Amino-8-ciklopentil-2-[5-(4-fluoro-benzilamino)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, N[6-(6-Amino-8-ciklopentil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2- iiamino)-piridin-3-il]-metansulfonamid, 6-Amino-8-ciklopentil-2-(5-metansulfonil-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, 6-Amino-8-ciklopentil-2-(5-fenil-piridin-2-ilamino)-8H~pirido[2, 3- d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-[5-(2-metoksi-etoksi)-piridin-2-ilamino]-5-rnetil-8H- pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-[5-(2-metoksi-etilamino)-piridin-2-ilamino]-5-metil- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-2-(5-azetidin-l-il-piridin-2-ilamino)-8-ciklopentil-5-metil-8H- pirido[2, 3-d]pirimidin-7-on, 6-Acetil-2-(5-azepan-l-il-piridin-2-ilamino)-8-ciklopentil-5-metil-8H- pirido[2, 3-d]pirimidin-7-on, N-[6-(6-Acetil-8-ciklopentil-5-metil-7-okso-7, 8-dihidro-pirido[2, 3- d]pirimidin-2-ilamino)-piridin-3-il]-acetamid, 6-Acetil-8-ciklopentil-5-metil-2-(5-fenilamino-piridin-2-ilamino)-8H- pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-[5-(4-fluoro-benzilamino)-piridin-2-ilamino]-5-metil- 8H-pirido[2, 3-d]pirimidin-7-on, N-[6-(6-Acetil-8-ciklopentil-5-metil-7-okso-7, 8-dihidro-pirido[2, 3- d]pirimidin-2-ilamino)-piridin-3-il]-metansulfonamid, 6-Acetil-8-ciklopentil-2-(5-metansulfonil-piridin-2-ilamino)-5-metil-8H- pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-5-metil-2-(5-fenil-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, 6-Benzil-8-ciklopentil-2-f5-(2-metoksi-etoksi)-piridin-2-ilamino]-8H- pirido[2, 3-dJpirimidin-7-on, 6-Benzil-8-ciklopentil-2-[5-(2-metoksi-etilamino)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidui-7-on, 2-(5-Azetidin-l-il-piridin-2-ilamino)-6-benzil-8-ciklopentil-8H-pirido[2, 3- d]pirimidin-7-on. 2-(5-Azepan-l-il-piridin-2-ilamino)-6-benzil-8-ciklopentil-8H-pirido[2, 3- d]pirimidin-7-on, N-[6-(6-Benzil-8-ciklopentil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2- ilamino)-piridin-3-il]-acetamid, 6-Benzil-8-ciklopentil-2-(5-fenilamino-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, 6-Benzil-8-ciklopentil-2-[5-(4-fluoro-benzilamino)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, N-[6-(6-Benzil-8-ciklopentil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2- ilamino)-piridin-3-il]-metansulfonamid, 6-Benzil-8-ciklopentil-2-(5-metansulfonil-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, 6-Benzil-8-ciklopentil-2-(5-fenil-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin- 7-on, 8-Ciklopentil-6-hidroksimetil-2-[5-(2-metoksi-etoksi)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-hidroksimetil-2-[5-(2-metoksi-etilamino)-piridin-2-ilamino]- 8H-pirido[2, 3-d]pirimidin-7-on, 2-(5-Azetidin-l-il-piridin-2-ilamino)-8-ciklopentil-6-hidroksimetil-8H- pirido[2, 3-d]pirimidin-7-on, 2-(5-Azepan-l-il-piridin-2-ilamino)-8-ciklopentil-6-hidroksimetil-8H- pirido[2, 3-d]pirimidin-7-on, N-[6-(8-Ciklopentil-6-hidroksimetil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin- 2-ilamino)-piridin-3-il]-acetamid, 8-Ciklopentil-6-hidroksimetil-2-(5-fenilamino-piridin-2-ilamino)-8H- pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-2-[5-(4-fluoro-benzilamino)-piridin-2-ilamino]-6-hidroksimetil- 8H-pirido[2, 3-d]pirimidin-7-on, N-[6-(8-Ciklopentil-6-hidroksimetil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin- 2-ilamino)-piridin-3-il]-metansulfonamid, 8-Ciklopentil-6-hidroksimetil-2-(5-metansulfonil-piridin-2-ilamino)-8H- pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-hidroksimetil-2-(5-fenil-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, 8-Ciklopentil-6-etil-2-|5-(2-mctoksi-etoksi)-piridin-2-i]amino]-8H-pirido[2, 3- d]pirimidin-7-on, 8-Ciklopentil-6-etil-2-[5-(2-metoksi-et. i1amino)-piridin-2dlamino]-8H- pirido[2, 3-d]pirimidin-7-on, 2-(5-Azetidin-l -il-piridin-2-ilamino)-8-ciklopentil-6-ctil-8H-pirido[2, 3-d]pirimidin-7-on, 2-(5-Azepan-l-il-piridin-2-ilamino)-8-ciklopentil-6-etil-8H-pirido[2, 3- d]pirimidin-7-on, N-[6-(8-Ciklopentil-6-etil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2- ilamino)-piridin-3-il]-acetamid, 8-Ciklopentil-6-etil-2-(5-fenilamino-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, 8-Ciklopentil-2-[5-(4-fluoro-benzilamino)-piridin-2-ilamino]-6-etil-8H- pirido[2, 3-d]pirimidin-7-on, N-[6-(8-Ciklopentil-6-etil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2- ilamino)-piridin-3-il]-metansulfonamid, 8-Ciklopentil-6-etil-2-(5-metansulfonil-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, 8-Ciklopentil-6-etil-2-(5-fenil-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7- on, 6-Bromo8-ciklopentil-2-[5-(piperazin-l-karbonil)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-[5-(3, 5-dimetil-piperazin-l-karbonil)-piridin-2- ilamino]-8H-pirido[2, 3-d]pirimidin-7-on, 2-[5-(3-Amino-pirolidin-l-karbonil)-piridin-2-ilamino]-6-bromo-8-ciklopentil- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-[5-(morfolin-4-karbonil)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-5-metil-2-[5-(piperazin-l-karbonil)-piridin-2-ilamino]- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-[5-(3, 5-dimetil-piperazin-l-karbonil)-piridin-2- ilamino]-8H-pirido[2, 3-d]pirimidin-7-on, 2-[5-(3-Amino-pirolidin-l-karbonil)-piridin-2-ilamino]-6-bromo-8-ciklopentil- 5-metil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-5-metil-2-[5-(morfolin-4-karbonil)-piridin-2-ilamino]- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-5-metil-2-[5-(piperazin-l-karbonil)-piridin-2-ilamino]- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-[5-(3, 5-dimetil-piperazin-l-karbonil)-piridin-2- ilamino]-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-2-[5-(3-amino pirolidin-l-karbonil)-piridin-2-ilamino]-8-ciklopentil-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-5-metil-2-[5-(morfolin-4-karbonil)-piridin-2-ilamino]- 8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-etil-2-[5-(piperazin-l-karbonil)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-2-[5-(3, 5-dimetil-piperazin-l-karbonil)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 2-[5-(3-Amino-pirolidin-l-karbonil)-piridin-2-ilamino]-8-ciklopentil-6-etil- 8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-etil-2-[5-(morfolin-4-karbonil)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-[5-(piperazin-l-sulfonil)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-[5-(morfolin-4-sulfonil)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 2-[5-(3-Amino-pirolidin-l-sulfonil)-piridin-2-ilamino]-6-bromo-8-ciklopentil- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-[5-(3, 5-dimetil-piperazin-l-sulfonil)-piridin-2- ilamino]-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-5-rnetil-2-[5-(piperazin-l-sulfonil)-piridin-2-ilamino]- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-5-metil-2-[5-(morfolin-4-sulfonil)-piridin-2-ilamino]- 8H-pirido[2, 3-d]pirimidin-7-on, 2-[5-(3-Amino-pirolidin-l-sulfonil)-piridin-2-ilamino]-6-bromo-8-ciklopentil- 5-metil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-[5-(3, 5-dimetil-piperazin-l-sulfonil)-piridin-2- ilamino]-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-etil-2-[5-(piperazin-l-sulfonil)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-etil-2-[5-(morfolin-4-sulfonil)-piridin-2-ilamino]-8H- pirido[2, 3-d]pirimidin-7-on, 2-[5-(3-Amino-pirolidin-l-sulfonil)-piridin-2-ilamino]-8-ciklopentil-6-etil-8H- pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-2-[5-(3, 5-dimetil-piperazin-l-sulfonil)-piridin-2-ilamino]-6-etil- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-5-metil-2-[5-(piperazin-l-sulfonil)-piridin-2-ilamino]- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-5-metil-2-[5-(morfolin-4-sulfonil)-piridin-2-ilamino]- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-2-[5-(3-amino-pirolidin-l-sulfonil)-piridin-2-ilamino]-8-ciklopentil-5- metil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-[5-(3, 5-dimetil-piperazin-l-sulfonil)-piridin-2-ilamino]-5-mctil-8H-pirido[2, 3-d]pirimidin-7-on, i 6-Acetil-8-ciklopentil-5-metil-2-([l, 6]naftiridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, 6-Acetil-8-ciklopentil-2-[5-( 1, 1 -diokso-116-tiomorfolin-4-il)-piridin-2-ilamino]-5-metil-8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-hidroksimetil-5-metil-2-(5-piperazin-l-il-piridin-2-ilamino- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Acelil-2-(3-hl()ro-5-piperazin-l-il-piiidin-2-ilamino)-8-ciklopentil-5-metil- 8H-pirido[2, 3-d]pirimidin-7-on, 4-[6-Acetil-5-metil-7-okso-2-(piridin-2-ilamino)-7H-pirido[2, 3-d]pirimidin-8-il]-cikloheksankarboksilatna kiselina, 4-[6-Acetil-2-(5-dimetilamino-piridin-2-ilamino)-5-metil-7-okso-7H-pirido[2, 3-d]pirimidin-8-il]-cikloheksankarboksilatna kiselina, 6-Bromo-8-ciklopentil-5-metil-2-[5-(piperazin-l-sulfonil)-piridin-2-ilamino]- 8H-pirido[2, 3-d]pirimidin-7-on, 6-(8-Ciklopentil-6-etil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino)-3-piperazin-1 -il-piridin-2-karboksilatna kiselina, 2-(6-Acetil-5-piperazin-l-il-piridin-2-ilamino)-8-ciklopentil-6-etil-8H-pirido[2, 3-d]pirimidin-7-on, 3-{2-[6-(8-Ciklopentil-6-etil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino)-piridin-3-iloksi]-etoksi}-propionatna kiselina, [6-(8-Ciklopentil-6-etil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-2-ilamino)-piridin-3-iloksi]-acetatna kiselina, 8-Ciklopentil-2-(5-{2-[2-(5-metil-piridin-2-il)-etoksi]-etoksi}-piridin-2- ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 2-[5-(3-Benzensulfonil-propoksi)-piridin-2-ilamino]-8-ciklopentil-8H- pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-etil-2-{5-[2-(2-metoksi-etoksi)-etoksi]-piridin-2-ilamino}-8H- pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-2-(5-{[3-(3, 5-dimetil-piperazin-l-il)-propil]-metil-amino}- piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-2-{5-[(3-imidazol-l-il-propil)-metil-amino]-piridin-2-ilamino}- 8H-pirido[2, 3-d]pirimidin-7-on, 6-Acetil-5-metil-2-(5-metil-2-piridin-2-ilamino)-8-piperidin-4-il-8H- pirido[2, 3-d]pirimidin-7-on, 6-Acetil-2-[5-(3, 4-dihidroksi-pirolidin-l-il)-piridin-2-ilamino]-8-metoksimetil- 5-metil-8H-pirido[2, 3-d]pirimidin-7-on.
8. Jedinjenje u skladu sa patentnim zahtevom 10 naznačeno time što je izabrano iz grupe koja sadrži: 8-Ciklopentil-2-(piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on hidrohlorid, 8-Ciklopentil-6-etil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on hidrohlorid, Hidrohlorid etil estra 8-ciklopentil-7-okso-2-(5-piperazin-l-il-piridin-2-ilamino)-7, 8-dihidro-pirido[2, 3-d]pirimidin-6-karboksilatne kiseline, 6 Amino-8-ciklopentil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-dJpirimidin-7-on hidrohlorid, 6-Bromo-8-ciklopentil-2-[5-((R)-1-metil-1-pirolidin-2-il)-piridin-2-ilamino]-8H-pirido[2, 3-d]pirimidin-7-on hidrohlorid, 6-Bromo-8-cikloheksil-2-(piridin-2-il-amino)-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-2-metil-8H-pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-5-metil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H- pirido[2, 3-d]pirimidin-7-on, 8-Ciklopentil-6-fluoro-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on hidrohlorid, 8-Ciklopentil-6-metil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on hidrohlorid, 8-Ciklopentil-6-izobutoksi-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on hidrohlorid, 6-Benzil-8-ciklopentil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on hidrohlorid, 8-Ciklopentil-6-hidroksimetil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on hidrohlorid, Etil estar 2-[5-(4-terc-butoksikarbonil-piperazin-l-il)-piridin-2-ilamino]-8-ciklopentil-5-metil-7-okso-7, 8-dihidro-pirido[2, 3-d]pirimidin-6-karboksilatne kiseline, 6-Acetil-8-ciklopentil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H-pirido[2, 3- d]pirimidin-7-on, 6-Acetil-8-ciklopentil-5-metil-2-(5-piperazin-l-il-piridin-2-ilamino)-8H- pirido[2, 3-d]pirimidin-7-on, 6-Bromo-8-ciklopentil-5-metil-2-(piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on, i 6-bromo-8-ciklopentil-2-(piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on.
9.    6-Acetil-8-ciklopentil-5-metil-2-(5-piperazin-1 -il-piridin-2-ilamino)-8H-pirido[2, 3-d]pirimidin-7-on.
10.    Postupak za lečenje oboljenja ili stanja izazvanih abnormalnom proliferacijom ćelija kod sisara, uključujući ljude, koji uključuje primenu na navedenom sisaru određene količine jedinjenja u skladu sa patentnim zahtevom 1, naznačene time što je efikasna u lečenju takvog stanja ili oboljenja.
11.    Postupak u skladu sa patentnim zahtevom 14, naznačen time što je oboljenje ili stanje koje se tretira izabrano iz grupe koja sadrži vaskularnu proliferaciju glatkih mišića povezanu sa aterosklerozom, posthirurške vaskularne stenoze i restenoze i endometrioze.
12.    Postupak za lečenje oboljenja ili stanja izazvanih infekcijama koje su izabrane iz grupe koja sadrži virusne infekcije kao što DNA virusi, kao herpesi i RNA virusi kao HIV i gljivične infekcije kod sisara, uključujući i ljude, koji uključuje primenu na navedenom sisaru one količine jedinjenja u skladu sa patentnim zahtevom 1, koja je efikasna u lečenju takvog stanja ili oboljenja.
13.    Postupak za lečenje oboljenja izabranih iz grupe koja sadrži autoimune bolesti izabrane iz grupe koja sadrži psorijaze, inflamacije kao reumatoidni artritis, lupus, dijabetes tip 1, dijabetičnu nefropatiju, multiple sklerozu, glomerulonefritis, odbacivanje transplantiranog organa, uključujući bolest domaćina kao reakcija na graft kod sisara, uključujući ljude, koji uključuje primenu na navedenom sisaru one količine jedinjenja u skladu sa patentnim zahtevom 1, koja je efikasna u lečenju takvog stanja ili oboljenja.
14.    Postupak za lečenje neurodegenerativnih oboljenja, kao što je Alchajmerova bolest kod sisara, uključujući ljude, koji obuhvata primenu na navedenom sisaru one količine jedinjenja u skladu sa patentnim zahtevom 1 koja je efikasna u lečenju takvog stanja ili oboljenja.
15. Postupak u skladu sa patentnim zahtevom 14, naznačen time je abnormalna proliferacija ćelija kancer izabran iz grupe koja sadrži kancere dojke, ovarijuma, cerviksa, prostate, testisa, ezofagusa, stomaka, kože, pluća, kostiju, kolona, pankreasa, tiroide, bilijarnih pasaža, bukalne duplje i faringsa (oralno), usne, jezika, usta, faringsa, tankog creva, kolon-rektuma, debelog creva, rektuma, mozga i centralnog nervnog sistema, glioblastomu, neuroblastomu, keratokantomu, epidermoidni karcinom, karcinom velike ćelije, adenokarcinom, adenom, adenokarcinom, folikularni karcinom, nediferencirani karcinom, papilarni karcinom, seminom, melanom, sarkom, karcinom bešike, karcinom jetre, karcinom bubrega, mijeloidna oboljenja, limfoidna oboljenja, Hočkins, ćelije folikule dlake i leukemija.
MEP-461/08A 2002-01-22 2003-01-10 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES MEP46108A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35087702P 2002-01-22 2002-01-22
PCT/IB2003/000059 WO2003062236A1 (en) 2002-01-22 2003-01-10 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES

Publications (2)

Publication Number Publication Date
ME00230B true ME00230B (me) 2011-02-10
MEP46108A MEP46108A (en) 2011-02-10

Family

ID=27613435

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-461/08A MEP46108A (en) 2002-01-22 2003-01-10 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES

Country Status (52)

Country Link
US (4) US6936612B2 (me)
EP (1) EP1470124B1 (me)
JP (1) JP4291696B2 (me)
KR (2) KR20060111716A (me)
CN (3) CN101906104B (me)
AP (1) AP1767A (me)
AR (2) AR038814A1 (me)
AT (1) ATE314370T1 (me)
AU (1) AU2003237009B2 (me)
BE (1) BE2017C005I2 (me)
BR (2) BR122016021801B8 (me)
CA (1) CA2473026C (me)
CO (1) CO5700765A2 (me)
CR (1) CR20120129A (me)
CY (2) CY1105686T1 (me)
DE (1) DE60303009T2 (me)
DK (1) DK1470124T3 (me)
DO (1) DOP2003000561A (me)
EA (1) EA007395B3 (me)
EC (2) ECSP045201A (me)
ES (1) ES2251677T3 (me)
FR (1) FR17C1012I2 (me)
GE (1) GEP20063909B (me)
GT (1) GT200300005A (me)
HN (1) HN2003000039A (me)
HR (1) HRP20040660B1 (me)
HU (2) HUS1700009I1 (me)
IL (3) IL162721A0 (me)
IS (1) IS2423B (me)
LT (1) LTC1470124I2 (me)
LU (1) LUC00009I2 (me)
MA (1) MA27166A1 (me)
ME (1) MEP46108A (me)
MX (1) MXPA04005939A (me)
MY (1) MY134818A (me)
NI (1) NI200300008A (me)
NL (1) NL300863I2 (me)
NO (2) NO329350B1 (me)
NZ (1) NZ534069A (me)
OA (1) OA12755A (me)
PA (1) PA8563701A1 (me)
PE (1) PE20030975A1 (me)
PL (2) PL220952B1 (me)
RS (1) RS51044B (me)
SI (1) SI1470124T1 (me)
SV (1) SV2004001459A (me)
TN (1) TNSN04126A1 (me)
TW (1) TWI343920B (me)
UA (1) UA79444C2 (me)
UY (1) UY27617A1 (me)
WO (1) WO2003062236A1 (me)
ZA (1) ZA200404840B (me)

Families Citing this family (327)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
EP1417207B1 (en) * 2000-08-04 2005-08-31 Warner-Lambert Company Llc Process for preparing 2-(4-pyridyl) amino-6-dialkyloxyphenyl-pyrido(2,3-d)pyrimidin-7-ones
US6960662B2 (en) * 2000-08-04 2005-11-01 Warner-Lambert Company Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones
CZ20032416A3 (cs) * 2001-02-12 2004-07-14 F. Hoffmann-La Roche Ag 6-Substituované pyridopyrimidiny
JP4166991B2 (ja) * 2001-02-26 2008-10-15 田辺三菱製薬株式会社 ピリドピリミジンまたはナフチリジン誘導体
US20030100572A1 (en) * 2001-06-21 2003-05-29 Ariad Pharmaceuticals,Inc. Novel pyridopyrimidones and uses thereof
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
DE60303009T2 (de) 2002-01-22 2006-07-13 Warner-Lambert Co. Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one
RU2324695C2 (ru) 2002-08-06 2008-05-20 Ф.Хоффманн-Ля Рош Аг 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38
US7112676B2 (en) 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
EP1571146A4 (en) 2002-12-10 2010-09-01 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
CN100497339C (zh) 2003-04-10 2009-06-10 霍夫曼-拉罗奇有限公司 嘧啶并化合物
JP4053073B2 (ja) * 2003-07-11 2008-02-27 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 選択的ｃｄｋ４阻害剤のイセチオン酸塩
NZ544756A (en) 2003-07-22 2009-09-25 Astex Therapeutics Ltd 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
SG145695A1 (en) * 2003-07-29 2008-09-29 Xenon Pharmaceuticals Inc Pyridyl derivatives and their use as therapeutic agents
WO2005047284A1 (en) * 2003-11-13 2005-05-26 F. Hoffmann-La Roche Ag Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
JP2007513967A (ja) * 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
CN1918158B (zh) * 2004-02-14 2011-03-02 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
JP2007523151A (ja) * 2004-02-18 2007-08-16 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ２−（ピリジン−３−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
JP4163738B2 (ja) * 2004-06-11 2008-10-08 日本たばこ産業株式会社 癌の治療用の５−アミノ−２，４，７−トリオキソ−３，４，７，８−テトラヒドロ−２Ｈ−ピリド’２，３−ｄ！ピリミジン誘導体及び関連化合物
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
CA2586761A1 (en) 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
EP1845973B1 (en) * 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
AU2006207321B2 (en) * 2005-01-21 2012-09-06 Astex Therapeutics Limited Pharmaceutical compounds
EP1845975A1 (en) * 2005-01-21 2007-10-24 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8680092B2 (en) 2005-02-25 2014-03-25 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic compound and medicinal use thereof
MY145343A (en) * 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
PE20061193A1 (es) * 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
RS52711B (sr) 2005-05-10 2013-08-30 Incyte Corporation Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih
KR100734837B1 (ko) * 2005-09-16 2007-07-03 한국전자통신연구원 다중 생체 인식 시스템 및 그 방법
WO2007036791A1 (en) * 2005-09-28 2007-04-05 Ranbaxy Laboratories Limited Pyrido-pyridimidine derivatives useful as antiinflammatory agents
US8044062B2 (en) * 2005-10-07 2011-10-25 Exelixis, Inc. Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
US20090142337A1 (en) * 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
EP2032134B1 (en) 2006-05-09 2015-06-24 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
RU2009108006A (ru) * 2006-09-08 2010-10-20 Пфайзер Продактс Инк. (Us) Синтез 2-(пиридин-2-иламино)-пиридо[2, 3-d]пиримидин-7-онов
GEP20115306B (me) 2006-09-15 2011-10-10 Pfizer Prod Inc
WO2008150260A1 (en) * 2007-06-06 2008-12-11 Gpc Biotech, Inc. 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
BRPI0715566A2 (pt) * 2006-10-16 2013-07-02 Gpc Biotech Inc composto, prà-droga, composiÇço farmacÊutica, uso de um composto, mÉtodo para inibir a proliferaÇço de cÉlulas e mÉtodo para sintetizar um composto
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JP2010509265A (ja) * 2006-11-09 2010-03-25 エフ．ホフマン−ラ ロシュ アーゲー キナーゼ阻害剤としての置換６−フェニル−ピリド［２，３−ｄ］ピリミジン−７−オン誘導体及びそれの使用方法
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
KR20160085917A (ko) 2007-10-05 2016-07-18 젠자임 코포레이션 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
MX2010010975A (es) 2008-04-07 2010-11-01 Amgen Inc Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
PL2315756T3 (pl) 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
KR101353857B1 (ko) * 2008-08-22 2014-01-21 노파르티스 아게 Ｃｄｋ 억제제로서 피롤로피리미딘 화합물
JP2012504646A (ja) * 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
CN102231983A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
US8309593B2 (en) 2008-10-03 2012-11-13 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
PA8852901A1 (es) * 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
EA031116B1 (ru) 2009-04-03 2018-11-30 Ф. Хоффманн-Ля Рош Аг КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ
CA2761896A1 (en) * 2009-05-13 2010-11-18 The University Of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
EP2474540A4 (en) * 2009-08-31 2013-03-13 Nippon Chemiphar Co GPR119 AGONIST
CA2776770A1 (en) * 2009-10-09 2011-04-14 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
UA105813C2 (uk) 2009-11-06 2014-06-25 Плексікон, Інк. Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти)
CA2784749C (en) 2009-12-18 2017-12-12 E. Premkumar Reddy Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
AU2011240735B2 (en) 2010-04-13 2015-01-29 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4/6) inhibitor and an mTOR inhibitor for treating cancer
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
US8680099B2 (en) * 2010-06-10 2014-03-25 Afraxis Holdings, Inc. 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
EP2580320B1 (en) 2010-06-14 2018-08-01 The Scripps Research Institute Reprogramming of cells to a new fate
DK2600719T3 (da) 2010-08-05 2014-12-15 Univ Temple 2-substituerede 8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-carbonnitriler og anvendelser deraf
MX379532B (es) 2010-10-25 2025-03-10 G1 Therapeutics Inc Inhibidores de cdk.
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
WO2012068381A2 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
PL2672967T3 (pl) 2011-02-07 2019-04-30 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania ku temu
PT2688887E (pt) 2011-03-23 2015-07-06 Amgen Inc Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3
AU2012262489A1 (en) 2011-05-27 2013-04-04 Icahn School Of Medicine At Mount Sinai Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof
UA114906C2 (uk) * 2012-03-14 2017-08-28 Люпін Лімітед Гетероциклільні сполуки як інгібітори мек
WO2013148748A1 (en) 2012-03-29 2013-10-03 Francis Xavier Tavares Lactam kinase inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
DK2872491T3 (da) 2012-07-11 2021-08-09 Blueprint Medicines Corp Inhibitorer af fibroblastvækstfaktorreceptoren
AU2013296237B2 (en) 2012-08-03 2019-05-16 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
BR112015003153A2 (pt) 2012-08-17 2017-07-04 Concert Pharmaceuticals Inc baricitinib deuterado
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US20140199728A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
PL2958916T3 (pl) * 2013-02-21 2019-01-31 Pfizer Inc. Stałe postacie selektywnego inhibitora CDK4/6
US20140271460A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly Active Anti-Neoplastic and Anti-Proliferative Agents
US9527857B2 (en) 2013-03-15 2016-12-27 GI Therapeutics, Inc. HSPC-sparing treatments for RB-positive abnormal cellular proliferation
AU2014235462C1 (en) 2013-03-15 2018-11-01 Concert Pharmaceuticals, Inc. Deuterated palbociclib
TWI649318B (zh) 2013-04-19 2019-02-01 英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
WO2014183520A1 (zh) * 2013-05-17 2014-11-20 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
BR112016008849B8 (pt) 2013-10-25 2022-09-06 Blueprint Medicines Corp Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas
EP4512480A3 (en) * 2013-12-20 2025-05-07 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of cdk and erk inhibitors
CN105916848B (zh) 2013-12-31 2018-01-09 山东轩竹医药科技有限公司 激酶抑制剂及其用途
US9949976B2 (en) 2013-12-31 2018-04-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015161283A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
ES2873959T3 (es) 2014-05-28 2021-11-04 Piramal Entpr Ltd Combinación farmacéutica que comprende un inhibidor de CDK y un inhibidor de tiorredoxina reductasa para el tratamiento del cáncer
US9878994B2 (en) 2014-07-24 2018-01-30 Beta Pharma Inc. 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof
WO2016015598A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
EP3174878A4 (en) * 2014-07-31 2017-12-27 Sun Pharmaceutical Industries Limited A process for the preparation of palbociclib
AR101504A1 (es) * 2014-08-11 2016-12-21 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6
WO2016024249A1 (en) * 2014-08-14 2016-02-18 Sun Pharmaceutical Industries Limited Crystalline forms of palbociclib
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN105111201B (zh) * 2014-10-16 2017-01-11 上海页岩科技有限公司 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN105622638B (zh) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
WO2016066420A1 (en) * 2014-10-29 2016-05-06 Sandoz Ag Crystalline forms of palbociclib monohydrochloride
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
EP4183806A3 (en) 2014-11-12 2023-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
CN104496983B (zh) 2014-11-26 2016-06-08 苏州明锐医药科技有限公司 一种帕博西尼的制备方法
CN104447743B (zh) 2014-11-26 2016-03-02 苏州明锐医药科技有限公司 帕博西尼的制备方法
WO2016090257A1 (en) * 2014-12-05 2016-06-09 Crystal Pharmatech Inc. Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
WO2016092442A1 (en) * 2014-12-08 2016-06-16 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline forms of palbociclib acetate
EP4205743A1 (en) 2014-12-31 2023-07-05 Shenzhen Pharmacin Co., Ltd. Pharmaceutical composition and preparation method therefor
CN105732615B (zh) * 2014-12-31 2018-05-01 山东轩竹医药科技有限公司 Cdk激酶抑制剂
CN104610254B (zh) * 2015-01-26 2017-02-01 新发药业有限公司 一种帕博赛布的低成本制备方法
CZ201589A3 (cs) 2015-02-11 2016-08-24 Zentiva, K.S. Pevné formy soli Palbociclibu
TWI690533B (zh) 2015-02-12 2020-04-11 南北兄弟藥業投資有限公司 Ｃｄｋ類小分子抑制劑的化合物及其用途
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
EP3078663A1 (en) 2015-04-09 2016-10-12 Sandoz Ag Modified particles of palbociclib
CN106795159B (zh) * 2015-04-22 2018-12-28 江苏恒瑞医药股份有限公司 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
TWI696617B (zh) * 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
WO2016194831A1 (ja) * 2015-05-29 2016-12-08 帝人ファーマ株式会社 ピリド［３，４－ｄ］ピリミジン誘導体及びその薬学的に許容される塩
HUE047477T2 (hu) 2015-06-04 2020-04-28 Pfizer Palbociclib szilárd dózisformái
CN104892604B (zh) * 2015-06-19 2016-08-24 北京康立生医药技术开发有限公司 一种cdk4抑制剂的合成方法
CN106699785A (zh) * 2015-07-13 2017-05-24 南开大学 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
US10526326B2 (en) 2015-08-05 2020-01-07 Ratiopharm Gmbh Crystalline form and acetic acid adducts of palbociclib
CN105085517B (zh) * 2015-08-06 2016-11-23 天津华洛康生物科技有限公司 一种结晶型帕博西尼游离碱水合物及其制备方法
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
HU230962B1 (hu) 2015-10-28 2019-06-28 Egis Gyógyszergyár Zrt. Palbociclib sók
CN106632311B (zh) 2015-11-02 2021-05-18 上海科胜药物研发有限公司 一种帕博西尼晶型a和晶型b的制备方法
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
CN105418603A (zh) * 2015-11-17 2016-03-23 重庆莱美药业股份有限公司 一种高纯度帕布昔利布及其反应中间体的制备方法
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
JP6951767B2 (ja) * 2015-12-13 2021-10-20 ハンジョウ イノゲート ファーマ カンパニー リミテッドＨａｎｇｚｈｏｕ Ｉｎｎｏｇａｔｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 抗癌薬として使用される複素環式化合物
EP3398947B1 (en) 2015-12-31 2024-08-28 Shanghai Pharmaceuticals Holding Co., Ltd. Nitrogen-containing fused heterocyclic compound, as well as preparation method, intermediate, composition and application thereof
CN105418609B (zh) * 2015-12-31 2017-06-23 山东大学 4‑(1,2,3‑三氮唑取代苯胺基)‑吡啶骈嘧啶酮衍生物及其制备方法与应用
CN106967061A (zh) * 2016-01-13 2017-07-21 常州方楠医药技术有限公司 帕博西林的盐、晶型及其制备方法
WO2017130219A1 (en) 2016-01-25 2017-08-03 Mylan Laboratories Limited Amorphous solid dispersion of palbociclib
WO2017145054A1 (en) 2016-02-24 2017-08-31 Lupin Limited Modified particles of crystalline palbociclib free base and process for the preparation thereof
WO2017161253A1 (en) 2016-03-18 2017-09-21 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN107266421B (zh) * 2016-04-08 2020-12-04 正大天晴药业集团股份有限公司 取代的苯并咪唑类衍生物
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
CA3018434A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
CN106336411B (zh) * 2016-04-27 2018-03-06 上海医药集团股份有限公司 Cdk4/6抑制剂帕博西尼高纯度原料药的制备工艺及用途
CN105949189B (zh) * 2016-06-05 2017-09-22 童明琼 一种用于治疗乳腺癌的帕博西尼的制备方法
EA201990187A1 (ru) 2016-07-01 2019-07-31 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
US10807978B2 (en) 2016-07-04 2020-10-20 Dr. Reddy's Laboratories Limited Process for preparation of palbociclib
EP3481825A1 (en) 2016-07-07 2019-05-15 Plantex Ltd. Solid state forms of palbociclib dimesylate
JP6563623B1 (ja) 2016-08-15 2019-08-21 ファイザー・インク ピリドピリミジノンｃｄｋ２／４／６阻害剤
CA3034875C (en) 2016-08-23 2024-05-28 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of hepatocellular carcinoma
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
WO2018065999A1 (en) 2016-10-07 2018-04-12 Mylan Laboratories Limited Novel polymorph of an intermediate for palbociclib synthesis
WO2018073574A1 (en) 2016-10-20 2018-04-26 Cipla Limited Polymorphic forms of palbociclib
EP3804724B1 (en) 2016-10-20 2022-12-07 Pfizer Inc. Cdk inhibitors for treating pah
CN106565707B (zh) * 2016-11-03 2019-01-04 杭州科巢生物科技有限公司 帕博西尼新合成方法
EP3538148A1 (en) 2016-11-08 2019-09-18 Dana-Farber Cancer Institute Compositions and methods of modulating anti-tumor immunity
US20190275049A1 (en) 2016-11-16 2019-09-12 Pfizer Inc. Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
MY199852A (en) 2016-11-28 2023-11-25 Teijin Pharma Ltd Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof
SI3546458T1 (sl) 2016-11-28 2021-03-31 Teijin Pharma Limited Derivati ((piridin-2-il)-amino)pirido(3,4-d)pirimidina in ((piridazin-3-il)amino)pirido(3,4-d)pirimidina kot zaviralci CDK4/6 za zdravljenje npr. revmatoidnega artritisa, arterioskleroze, pljučne fibroze, možganske kapi ali raka
KR102513448B1 (ko) 2016-12-16 2023-03-23 씨스톤 파마슈티컬즈 Cdk4/6 억제제
TWI823845B (zh) 2017-01-06 2023-12-01 美商G1治療公司 用於治療癌症的組合療法
CN108191857B (zh) * 2017-01-24 2020-10-23 晟科药业（江苏）有限公司 6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
US10729692B2 (en) * 2017-02-26 2020-08-04 Institute For Cancer Research Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
AU2018229148B2 (en) * 2017-03-03 2022-08-04 Auckland Uniservices Limited FGFR kinase inhibitors and pharmaceutical uses
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
MX2019010981A (es) 2017-03-16 2020-09-07 Eisai R&D Man Co Ltd Terapias de combinacion para el tratamiento de cancer de mama.
CN108658855A (zh) * 2017-03-28 2018-10-16 中国海洋大学 一种含氮双环化合物及其制备方法和用途
CN108658854A (zh) * 2017-03-28 2018-10-16 中国海洋大学 一种生物碱化合物及其制备方法和作为海洋防污剂的应用
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MX2019015177A (es) 2017-06-16 2020-02-07 Beta Pharma Inc Formulaciones farmaceuticas de n-(2-(2-(dimetilamino)etoxi)-4-meto xi-5((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilam ida y las sales de ellas.
EP4455146A3 (en) 2017-06-29 2025-01-01 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
EA036060B1 (ru) * 2017-07-17 2020-09-21 Пфайзер Инк. Пиридопиримидиноновые ингибиторы cdk2/4/6
EA202090402A1 (ru) 2017-07-28 2020-05-19 Синтон Б.В. Фармацевтическая композиция, содержащая пальбоциклиб
CN109384767B (zh) * 2017-08-08 2020-05-05 江苏恒瑞医药股份有限公司 一种吡啶并嘧啶类衍生物的制备方法及其中间体
ES3049655T3 (en) 2017-08-31 2025-12-17 Novartis Ag Methods of selecting a treatment for breast cancer patients
CN107488175A (zh) * 2017-09-04 2017-12-19 上海微巨实业有限公司 一种帕博西林关键中间体的制备方法
US12043870B2 (en) 2017-10-02 2024-07-23 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
MX2020006587A (es) 2017-12-22 2020-12-10 Ravenna Pharmaceuticals Inc Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa.
CN108586452A (zh) * 2018-01-12 2018-09-28 重庆市碚圣医药科技股份有限公司 一种帕博西尼中间体的合成方法
WO2019148161A1 (en) 2018-01-29 2019-08-01 Beta Pharma, Inc. 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
CN108218861B (zh) * 2018-02-05 2019-07-23 黑龙江中医药大学 一种预防和治疗糖尿病的药物及其制备方法
WO2019157020A1 (en) 2018-02-06 2019-08-15 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
JP2021514975A (ja) 2018-02-27 2021-06-17 ファイザー・インク サイクリン依存性キナーゼ阻害剤およびｂｅｔ−ブロモドメイン阻害剤の組合せ
US20190292188A1 (en) 2018-02-27 2019-09-26 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
ES2991427T3 (es) 2018-05-04 2024-12-03 Incyte Corp Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
EP4309656A3 (en) 2018-05-14 2024-02-28 Pfizer Inc. Oral solution formulation
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
SI3802529T1 (sl) 2018-05-24 2024-03-29 Synthon B.V. Postopek za izdelavo palbocikliba
CN113166153B (zh) 2018-07-05 2024-11-01 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
CN117281814A (zh) 2018-07-23 2023-12-26 豪夫迈·罗氏有限公司 用pi3k抑制剂gdc-0077治疗癌症的方法
CA3107750A1 (en) 2018-07-27 2020-01-30 California Institute Of Technology Cdk inhibitors and uses thereof
CN120817904A (zh) 2018-08-24 2025-10-21 法码科思莫斯有限公司 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成
JP6952747B2 (ja) 2018-09-18 2021-10-20 ファイザー・インク がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
TW202027736A (zh) 2018-10-08 2020-08-01 瑞士商赫孚孟拉羅股份公司 用PI3Kα抑制劑及二甲雙胍治療癌症之方法
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020114519A1 (zh) * 2018-12-07 2020-06-11 杭州英创医药科技有限公司 作为cdk-hdac双通路抑制剂的杂环化合物
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CA3124569A1 (en) 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
WO2020140055A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020157709A1 (en) 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
MA54947A (fr) * 2019-02-15 2021-12-22 Incyte Corp Biomarqueurs de kinase 2 dépendant de la cycline et leurs utilisations
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
EP3976043A1 (en) 2019-05-24 2022-04-06 Pfizer Inc. Combination therapies using cdk inhibitors
CN113874036A (zh) 2019-05-24 2021-12-31 辉瑞公司 使用cdk抑制剂的联合治疗
CN112010844B (zh) * 2019-05-31 2023-07-25 中国药科大学 N-(嘧啶-2-基)香豆素-7-胺衍生物作为蛋白激酶抑制剂的制法和应用
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
TW202114685A (zh) * 2019-06-20 2021-04-16 大陸商江蘇恒瑞醫藥股份有限公司 藥物組合物以及其製備方法
CN110143948B (zh) * 2019-06-21 2021-05-14 上海博悦生物科技有限公司 Cdk4/6抑制剂、其药物组合物、制备方法及应用
JP7616794B2 (ja) 2019-07-07 2025-01-17 オレマ ファーマシューティカルズ インク． エストロゲン受容体アンタゴニストのレジメン
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021022172A1 (en) 2019-08-01 2021-02-04 Incyte Corporation A dosing regimen for an ido inhibitor
MX2022001940A (es) 2019-08-14 2022-05-10 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
IL290789B2 (en) 2019-08-26 2025-09-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN119930610A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
GEAP202415945A (en) 2019-10-14 2024-04-25 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
IL293347A (en) 2019-12-03 2022-07-01 Genentech Inc Combined therapies for the treatment of breast cancer
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
IL293940B1 (en) 2019-12-16 2026-01-01 Lunella Biotech Inc Selective cancer drugs cdk4/6 inhibitors
US12319690B2 (en) * 2019-12-16 2025-06-03 Lunella Biotech, Inc. Selective CDK 4/6 inhibitor cancer therapeutics
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021176349A1 (en) 2020-03-05 2021-09-10 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
EP4114401A1 (en) 2020-03-06 2023-01-11 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
WO2021183994A1 (en) * 2020-03-13 2021-09-16 Prosenestar Llc Pyrido[2,3-d]pyrimidin-7(8h)-ones as cdk inhibitors
CN114245753A (zh) * 2020-03-27 2022-03-25 江苏康宁杰瑞生物制药有限公司 用于肿瘤治疗的抗her2抗体与cdk抑制剂的组合
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
IL297165A (en) 2020-04-16 2022-12-01 Incyte Corp Soysag tricyclic CRS inhibitors
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
EP4652997A3 (en) 2020-05-19 2026-03-04 Pharmacosmos Holding A/s Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
EP4157847A4 (en) * 2020-05-28 2024-06-19 University of Washington Drug-like molecules and methods for the therapeutic targeting of viral rna structures
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CN113880809B (zh) 2020-07-03 2022-10-18 盛世泰科生物医药技术(苏州)有限公司 一种嘧啶类衍生物及其制备方法和应用
EP4667055A3 (en) 2020-07-15 2026-02-25 Pfizer Inc. Kat6 inhibitor methods and combinations for cancer treatment
US20230321042A1 (en) 2020-07-20 2023-10-12 Pfizer Inc. Combination therapy
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
CN114246841B (zh) * 2020-09-24 2024-02-02 南京济群医药科技股份有限公司 一种羟乙磺酸哌柏西利的组合物及药物
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
CN112569361B (zh) * 2020-12-30 2023-01-10 扬子江药业集团上海海尼药业有限公司 一种哌柏西利干混悬组合物及其制备方法
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022258023A1 (zh) * 2021-06-09 2022-12-15 郑州同源康医药有限公司 用作cdk激酶抑制剂的化合物及其应用
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
CA3224674A1 (en) 2021-07-07 2023-01-12 Pei Gan Tricyclic compounds as inhibitors of kras
EP4370515A1 (en) 2021-07-14 2024-05-22 Incyte Corporation Tricyclic compounds as inhibitors of kras
EP4370126A4 (en) 2021-07-16 2025-05-28 Dana-Farber Cancer Institute, Inc. Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
JP2024529430A (ja) 2021-07-26 2024-08-06 セルキュイティー インコーポレイテッド がんの処置における使用のための１－（４－｛［４－（ジメチルアミノ）ピペリジン－１－イル］カルボニル｝フェニル）－３－［４－（４，６－ジモルホリン－４－イル－１，３，５－トリアジン－２－イル）フェニル］尿素（ゲダトリシブ）およびその組合せ
CA3229855A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
CN113683612B (zh) * 2021-09-07 2022-06-17 山东铂源药业股份有限公司 一种帕布昔利布的制备方法
CN118119393A (zh) * 2021-09-14 2024-05-31 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
WO2023056421A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
IL312114A (en) 2021-10-14 2024-06-01 Incyte Corp Quinoline compounds as Kras inhibitors
JP2024542248A (ja) 2021-11-22 2024-11-13 インサイト・コーポレイション Ｆｇｆｒ阻害剤とｋｒａｓ阻害剤を含む併用療法
US20230203010A1 (en) 2021-12-03 2023-06-29 Incyte Corporation Bicyclic amine cdk12 inhibitors
AU2022408062B2 (en) 2021-12-10 2025-08-14 Eli Lilly And Company Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
US20250049802A1 (en) 2021-12-14 2025-02-13 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023114264A1 (en) 2021-12-15 2023-06-22 Eli Lilly And Company Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
TW202340215A (zh) 2021-12-22 2023-10-16 美商英塞特公司 Ｆｇｆｒ抑制劑之鹽及固體形式以及其製備方法
WO2023116884A1 (en) 2021-12-24 2023-06-29 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
CN114456180B (zh) * 2022-02-18 2023-07-25 贵州大学 用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
CR20240408A (es) 2022-03-07 2024-11-22 Incyte Corp Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2.
HU231594B1 (hu) * 2022-05-10 2025-03-28 Egis Gyógyszergyár Zrt. Palbociclibet és letrozolt tartalmazó gyógyszerkészítmény
WO2023250430A1 (en) 2022-06-22 2023-12-28 Incyte Corporation Bicyclic amine cdk12 inhibitors
EP4302755B1 (en) 2022-07-07 2025-08-20 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing an amino acid
EP4302832A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing glucono delta lactone
WO2024015731A1 (en) 2022-07-11 2024-01-18 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
CN117430597A (zh) * 2022-07-14 2024-01-23 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用
CN119604288A (zh) 2022-07-29 2025-03-11 辉瑞大药厂 用于治疗癌症的包含kat6抑制剂的给药方案
IL319242A (en) 2022-08-31 2025-04-01 Arvinas Operations Inc Estrogen Receptor Blocker Dosage Regimen
CN120456897A (zh) 2022-11-02 2025-08-08 佩特拉制药公司 用于治疗疾病的磷酸肌醇3-激酶(pi3k)变构色原酮抑制剂
CN120187416A (zh) 2022-11-11 2025-06-20 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
CN120344527A (zh) * 2022-12-16 2025-07-18 上海岸阔医药科技有限公司 化合物及其用途
WO2024132652A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024133726A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
CN120981721A (zh) 2023-03-30 2025-11-18 辉瑞大药厂 Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
WO2024220532A1 (en) 2023-04-18 2024-10-24 Incyte Corporation Pyrrolidine kras inhibitors
EP4698542A1 (en) 2023-04-18 2026-02-25 Incyte Corporation 2-azabicyclo[2.2.1]heptane kras inhibitors
WO2024231275A1 (en) 2023-05-05 2024-11-14 Astrazeneca Ab Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breast cancer
WO2024235844A1 (en) 2023-05-12 2024-11-21 Institut National de la Santé et de la Recherche Médicale Methods of preventing on-target genotoxicity induced by nucleases
WO2024254245A1 (en) 2023-06-09 2024-12-12 Incyte Corporation Bicyclic amines as cdk2 inhibitors
WO2025051337A1 (en) 2023-09-06 2025-03-13 Afyx Development A/S Compositions and methods for treating and preventing oral cancer
WO2025096738A1 (en) 2023-11-01 2025-05-08 Incyte Corporation Kras inhibitors
US20250177414A1 (en) 2023-12-04 2025-06-05 Genentech, Inc. Combination therapies for treatment of breast cancer
US20250195536A1 (en) 2023-12-13 2025-06-19 Incyte Corporation Bicyclooctane kras inhibitors
WO2025202854A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
WO2026025013A2 (en) 2024-07-26 2026-01-29 Pfizer Inc. Combination therapy using cdk4 inhibitors for cancer treatments
US20260053814A1 (en) 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ194045A (en) 1979-06-14 1984-09-28 Wellcome Found 6-(2,5-or 3,4-dialkoxybenzyl)-2,4-diamino-5-methylpyrido(2,3-d)pyrimidines
US4959474A (en) 1979-06-14 1990-09-25 Burroughs Wellcome Co. Dialkoxy pyridopyrimidine compounds
ZA803539B (en) 1979-06-14 1982-01-27 Wellcome Found Alkoxybenzylrimidines method for their preparation formulation thereof and their use in medicine
EP0278686A1 (en) 1987-02-07 1988-08-17 The Wellcome Foundation Limited Pyridopyrimidines methods for their preparation and pharmaceutical formulations thereof
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5426110A (en) 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
RU2191188C2 (ru) 1994-11-14 2002-10-20 Варнер-Ламберт Компани Производные 6-арилпиридо[2,3-d]-пиримидины и -нафтиридины, фармацевтическая композиция, обладающая ингибирующим действием клеточной пролиферации, вызываемой протеиновой тирозинкиназой, и способ ингибирования клеточной пролиферации
US5801183A (en) 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
JP2001511764A (ja) 1996-04-12 2001-08-14 住友製薬株式会社 ピペリジニルピリミジン誘導体
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
DE69839338T2 (de) * 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US6569878B1 (en) 1997-10-27 2003-05-27 Agouron Pharmaceuticals Inc. Substituted 4-amino-thiazol-2-yl compounds as cyclin-dependent kinase inhibitors
EE200000706A (et) * 1998-05-26 2002-06-17 Warner-Lambert Company Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
US6958333B1 (en) 1999-07-26 2005-10-25 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
EA005287B1 (ru) 1999-09-15 2004-12-30 Уорнер-Ламберт Компани Птеридиноны в качестве ингибиторов киназ
CN1433417A (zh) * 2000-01-27 2003-07-30 沃尼尔·朗伯公司 用于治疗神经变性疾病的吡啶并嘧啶酮衍生物
YU66502A (sh) * 2000-03-06 2005-09-19 Warner-Lambert Company 5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza
ES2311532T3 (es) 2000-08-04 2009-02-16 Warner-Lambert Company Llc 2-(4-pirdil)amino-6-dialcoxifenil-pirido(2.3-d)pirimidin-7-onas.
ES2230337T3 (es) 2000-09-01 2005-05-01 Glaxo Group Limited Derivados de oxindol.
GB0101686D0 (en) 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
CZ20032416A3 (cs) * 2001-02-12 2004-07-14 F. Hoffmann-La Roche Ag 6-Substituované pyridopyrimidiny
DE60210819T2 (de) 2001-12-17 2007-04-19 Smithkline Beecham Corp. Pyrazolopyridazinderivate
DE60303009T2 (de) 2002-01-22 2006-07-13 Warner-Lambert Co. Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one
US7189712B2 (en) 2002-10-10 2007-03-13 Smithkline Beecham Corporation 1,3-Oxazole compounds for the treatment of cancer
EP1567112B1 (en) 2002-11-22 2008-10-15 Smithkline Beecham Corporation THIAZOLIDIN-4-ONES FOR INHIBITING hYAK3 PROTEINS
WO2004063195A1 (en) * 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
JP2006516561A (ja) 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
DE602004016964D1 (de) 2003-02-27 2008-11-20 Smithkline Beecham Corp Neue verbindungen
JP4053073B2 (ja) 2003-07-11 2008-02-27 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 選択的ｃｄｋ４阻害剤のイセチオン酸塩
RU2009108006A (ru) 2006-09-08 2010-10-20 Пфайзер Продактс Инк. (Us) Синтез 2-(пиридин-2-иламино)-пиридо[2, 3-d]пиримидин-7-онов

Also Published As

Publication number Publication date
KR100669578B1 (ko) 2007-01-15
CY1105686T1 (el) 2010-12-22
US20050137214A1 (en) 2005-06-23
HRP20040660A2 (en) 2004-12-31
WO2003062236A1 (en) 2003-07-31
CN102295643B (zh) 2013-12-04
PL218692B1 (pl) 2015-01-30
NL300863I2 (nl) 2017-08-03
AR083686A2 (es) 2013-03-13
BR122016021801B1 (pt) 2021-02-09
GT200300005A (es) 2003-08-22
CA2473026A1 (en) 2003-07-31
EP1470124A1 (en) 2004-10-27
SV2004001459A (es) 2004-07-07
RS59804A (sr) 2006-12-15
JP4291696B2 (ja) 2009-07-08
LUC00009I2 (me) 2017-05-30
AP1767A (en) 2007-08-13
US7208489B2 (en) 2007-04-24
MA27166A1 (fr) 2005-01-03
LUC00009I1 (me) 2017-03-16
BRPI0307057B1 (pt) 2018-05-29
IL198243A (en) 2013-05-30
CY2017011I2 (el) 2017-11-14
MY134818A (en) 2007-12-31
NI200300008A (es) 2004-12-03
US6936612B2 (en) 2005-08-30
MXPA04005939A (es) 2005-01-25
FR17C1012I2 (fr) 2018-06-08
CN101001857A (zh) 2007-07-18
FR17C1012I1 (me) 2017-07-07
NO2017014I1 (no) 2017-04-19
ES2251677T3 (es) 2006-05-01
BR122016021801B8 (pt) 2021-05-25
ECSP045201A (es) 2004-08-27
EA200400860A1 (ru) 2004-12-30
OA12755A (en) 2006-07-03
CN102295643A (zh) 2011-12-28
WO2003062236A8 (en) 2003-12-24
ECSP105201A (es) 2010-02-26
GEP20063909B (en) 2006-08-25
IS7323A (is) 2004-06-16
CN101906104A (zh) 2010-12-08
TW200302224A (en) 2003-08-01
KR20040077759A (ko) 2004-09-06
PA8563701A1 (es) 2003-09-17
RS51044B (sr) 2010-10-31
HUS1700019I1 (hu) 2017-05-29
NO2017014I2 (no) 2017-04-19
HUS1700009I1 (hu) 2017-07-28
PE20030975A1 (es) 2003-11-12
LTC1470124I2 (lt) 2019-04-25
IL162721A0 (en) 2005-11-20
AR038814A1 (es) 2005-01-26
PL372046A1 (en) 2005-07-11
US7456168B2 (en) 2008-11-25
NZ534069A (en) 2007-03-30
CN101906104B (zh) 2013-06-05
LTPA2017013I1 (lt) 2017-05-25
PL391191A1 (me) 2005-07-11
NO20043484L (no) 2004-10-15
NO329350B1 (no) 2010-10-04
IL162721A (en) 2009-12-24
PL220952B1 (pl) 2016-01-29
IS2423B (is) 2008-10-15
ZA200404840B (en) 2005-09-28
HK1104296A1 (en) 2008-01-11
ATE314370T1 (de) 2006-01-15
CN101001857B (zh) 2011-06-22
EP1470124B1 (en) 2005-12-28
HN2003000039A (es) 2005-11-12
CR20120129A (es) 2012-06-12
BR0307057A (pt) 2004-10-26
EA007395B1 (ru) 2006-10-27
JP2005519909A (ja) 2005-07-07
AU2003237009B2 (en) 2008-10-02
US20030149001A1 (en) 2003-08-07
UY27617A1 (es) 2003-08-29
TNSN04126A1 (fr) 2007-03-12
HRP20040660B1 (hr) 2012-10-31
US20070179118A1 (en) 2007-08-02
HK1162026A1 (en) 2012-08-17
EA007395B3 (ru) 2018-02-28
AP2004003085A0 (en) 2004-09-30
CO5700765A2 (es) 2006-11-30
UA79444C2 (uk) 2007-06-25
DK1470124T3 (da) 2006-04-18
HK1146048A1 (en) 2011-05-13
CY2017011I1 (el) 2017-11-14
SI1470124T1 (sl) 2006-04-30
BRPI0307057B8 (pt) 2021-05-25
MEP46108A (en) 2011-02-10
DE60303009D1 (de) 2006-02-02
USRE47739E1 (en) 2019-11-26
TWI343920B (en) 2011-06-21
KR20060111716A (ko) 2006-10-27
DE60303009T2 (de) 2006-07-13
DOP2003000561A (es) 2003-09-15
CA2473026C (en) 2011-05-03
BE2017C005I2 (me) 2022-05-17

Similar Documents

Publication Publication Date Title
ME00230B (me) 2-(piridin -2-ilamino)-pirido(2,3-d) pirimidin-7-oni
JP7579402B2 (ja) 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６－（４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル）－３－（２，３－ジクロロフェニル）－２－メチルピリミジン－４（３ｈ）－オン誘導体及び関連化合物
CA2576269C (en) Combinations for the treatment of diseases involving cell proliferation
CA3124678A1 (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
IL303451A (en) Prmts inhibitors
CN114732910B (zh) P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
JP2008528468A5 (me)
CA3034705A1 (en) Inhibitors of cellular metabolic processes
JP2019163290A (ja) 新規グルタミナーゼ阻害剤
ES2652514T3 (es) Compuestos heteroaromáticos como ligandos de dopamina D1
CA2778686C (en) N-9-substituted purine compounds, compositions and methods of use
JP2012511588A5 (me)
AU2009258115B2 (en) Diazacarbazoles and methods of use
CN114599361A (zh) Prmt5抑制剂的药物组合物
JP2019524872A (ja) 癌の治療に有用なイミダゾピリミジン化合物
CA2817460A1 (en) Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
SG146694A1 (en) 1,1,1-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo-2,3-c pyridin-2- ylmethyl)pentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes
CA2782213A1 (en) 1,7-diazacarbazoles and their use in the treatment of cancer
HRP20250969T1 (hr) Triciklički parp1 inhibitori i njihove uporabe
JP7603740B2 (ja) シクロオレフィン置換複素芳香族化合物およびそれらの使用
JP2013511526A5 (me)
CN104447765A (zh) 三环化合物及其药物组合物和应用
JP6250062B2 (ja) がん、ウイルス感染症、及び肺疾患の処置のためのインドールの新規誘導体
HRP20151419T1 (hr) Derivati 2-okso-1-imidazolidinil imidazotiadiazola
RU2012138162A (ru) Производные пиридазина для использования в качестве агонистов каннабинода-2